BioSpace News Archive

Immunome, Inc. today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Equillium, Inc. today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono’s three-month option exercise period to acquire Equillium’s rights to itolizumab.

Aptevo Therapeutics Inc. today announced a presentation at The Essential Protein & Antibody Engineering Summit (PEGS) conference in Boston MA.

Innate Pharma SA reported its consolidated financial results for the quarter ending March 31, 2024.

Burning Rock Biotech Limited announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares to Class A ordinary shares from one ADS representing one Class A ordinary share to one ADS representing ten Class A ordinary shares will become effective on May 15, 2024.

Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the approval of multiple innovative medicines.

Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, provided a business update and reported financial results for the quarter ended March 31, 2024.

ElevateBio, LLC announced that the United States Patent and Trademark Office has issued to Life Edit, ElevateBio’s gene editing business, four new patents covering multiple enzymes.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT.

Alimera Sciences, Inc. today announced financial results for the first quarter of 2024.